Why the study?
To investigate the co-distributions of stroke and bleeding risks in Asian AF patients and evaluate the clinical benefits of OACs in those with a single stroke risk factor but high bleeding risk.
Does the use of oral anticoagulants reduce composite adverse events of ischaemic stroke, intracranial haemorrhage, or mortality in Asian patients with atrial fibrillation who have a single stroke risk factor but high bleeding risk?
Does the use of oral anticoagulants reduce composite adverse events of ischaemic stroke, intracranial haemorrhage, or mortality in Asian patients with atrial fibrillation who have a single stroke risk factor but high bleeding risk?
In AF patients with a single stroke risk factor and high bleeding risk, oral anticoagulants are associated with a significantly lower risk of ischemic stroke, intracranial hemorrhage, or mortality.
Answers are grounded in this paper and cite their sources.
May inform OAC decisions in high-bleeding-risk Asian AF with one stroke factor; leaves open RCT confirmation.
AIMS: To investigate the co-distributions of stroke and bleeding risks in Asian patients with atrial fibrillation (AF) and the clinical benefits of oral anticoagulants (OACs) among AF patients with a single stroke risk factor but at high bleeding risk. METHODS AND RESULTS: From 1 January 2001 to 31 December 2016, a total of 404 949 AF patients were retrospectively identified from Taiwan National Health Insurance Research Database. Stroke risk was assessed using the CHA2DS2-VASc score and was categorized into low risk (score = 0 for males and 1 for females), intermediate risk (i.e. a single non-sex stroke risk factor; score = 1 for males and 2 for females), and high risk (score ≥2 for males and ≥3 for females). A high risk of bleeding was defined as a HAS-BLED score ≥3. Around 57.5% of AF patients were at high risk for both stroke and bleeding, and most patients (97.6%) with a low stroke risk were also at low risk for bleeding. Around 18.3% of patients with a CHA2DS2-VASc score of 1 (males) or 2 (females) were at high bleeding risk, and the use of OACs in such patients was associated with a lower risk of composite adverse events of ischaemic stroke, intracranial haemorrhage, or mortality (4.19/100 person-years vs. 5.22/100 person-years, adjusted hazard ratio = 0.781, P = 0.04). CONCLUSION: For AF patients with an intermediate risk of stroke (i.e. a single non-sex stroke risk factor) but at high bleeding risk, the use of OACs was still significantly associated with a better overall clinical outcome.
No takes yet. Share an insight, caveat, or question.
Chao et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: